• Describe the immune cells and proinflammatory proteins that represent therapeutic targets in SLE including BAFF, type 1 interferon, and cytokines associated with JAK/STAT signaling
• Explain how dysregulated innate and adaptive immune responses lead to specific clinical manifestations and disease consequences in patients with SLE
• Evaluate the safety and efficacy of new and emerging SLE therapies that target its pathogenetic pathways
• Select treatments for patients with SLE based on their pathogenic rationale

This enduring TeleECHO activity will explore the use of JAK inhibitors for the management of rheumatoid arthritis (RA) through interactive case studies. Faculty will review emerging efficacy and safety data, discuss guideline recommended care of RA, and help clinicians identify candidates for treatment with JAK inhibitors.

This educational activity will explore the use of monoclonal antibodies for the treatment and prevention of COVID-19 in pediatric patients. A review of available clinical data will help clinicians identify candidates for therapy and select appropriate treatments based on the most up-to-date information.

This enduring TeleECHO educational series targets healthcare gaps related to the familiarity and understanding of CDK4/6 inhibitor clinical trial designs and results on efficacy, safety, and real-world studies, impacting outcomes through current practice patterns and treatment strategies in the management of HR+/HER2- metastatic breast cancer (mBC).

This case-based online enduring activity will cover the treatment and management of patients with Type 2 diabetes mellitus (T2D) who are at high risk for chronic kidney disease.

Oncology nurses are in an inherently valuable position to be in the frontline of breast cancer treatment for patients. Given identified gaps and faculty feedback, the instructional design of this program is a multi-pronged educational approach designed for an oncology nursing audience. 

This educational activity will assess the pathophysiology and disease domains of psoriatic arthritis as well as review FDA-approved agents and their roles in in treating the disease. Additionally, we will discuss the appropriateness of combination or monotherapy regimens and unanswered questions in this area.

This online activity will cover the pneumococcal vaccinations in specific populations.

This live virtual activity will help clinicians reduce the significant delay between onset of symptoms and diagnosis of axial spondyloarthritis (axSpA) by identifying patients with inflammatory back pain who should be promptly referred to a rheumatologist for further assessment. Case studies and engaging whiteboard animations on the features of axSpA and the consequences of delays in diagnosis create a memorable and practical learning experience.

This enduring activity will help clinicians reduce the significant delay between onset of symptoms and diagnosis of axial spondyloarthritis (axSpA) by identifying patients with inflammatory back pain who should be promptly referred to a rheumatologist for further assessment. Case studies and engaging whiteboard animations on the features of axSpA and the consequences of delays in diagnosis create a memorable and practical learning experience.

Pneumococcal disease caused by Streptococcus pneumoniae is the leading cause of pneumonia-related deaths and poses an important global public health concern. There are several vaccines available for prevention of this disease, but their implementation in the clinic is challenged by complex recommendations of their administration for various patient populations and by complicated guidelines for appropriate spacing and sequencing of vaccine schedules. Managed Care Specialists need to understand the nuances of pneumococcal vaccines to guide physicians on their appropriate use to reduce infections and improve clinical outcomes, particularly for at-risk patients. This educational activity will explore the impact of pneumococcal disease, pathophysiology of disease, guidelines recommendations, and strategies for managing vaccine hesitancy. In addition to a didactic presentation, the program features animations and case discussions to highlight the different aspects of this disease.

This online activity with an integrated case-based learning component will enable clinicians to recognize emerging targets in the management of anemia of chronic kidney disease (CKD) through an understanding of the underlying pathophysiology and clinical trials evaluating novel therapies. By integrating these data with the current standards of care in the management of anemia of CKD, clinicians will be better able to understand the role of multiple healthcare professionals in the management of this common complication of CKD. Additionally, the integrated case-based activity within this program will ensure that healthcare professionals can readily translate learnings to patient interactions, ensuring that patients and the healthcare team are aware fully aware of emerging therapeutic alternatives.

Through a series of informative lectures and podcast interviews, this educational series will target clinicians in the field of rheumatology who have patients with psoriatic arthritis. We will provide the latest information on clinical presentation, differential diagnosis, therapeutic targets, and clinical trial data on current and emerging therapies to help learners reduce both short- and long-term consequences of the disease.

This enduring activity will focus on the T-cell Immunoreceptor with Ig and ITIM Domains (TIGIT).

This enduring TeleECHO program will explore the role of real-world evidence in informing management decisions of elderly and frail patients with relapsed and refractory multiple myeloma (RRMM). A brief didactic presentation will discuss prognostic features and key management considerations for the elderly and frail patient populations. A summary of clinical trial data and real world evidence to inform treatment selection in the first-line and relapse settings will also be presented. Interactive case studies will illustrate strategies for patient counseling and treatment selection in elderly and frail patients with RRMM.

This enduring activity covers the pathogenesis of Metastatic Castration-resistant Prostate Cancer (mCRPC) and which patients may benefit from using PARP Inhibitor–based Combinations.

This interactive online activity will explore the diagnosis and management of hypertrophic cardiomyopathy (HCM). A didactic presentation by expert faculty will review guideline recommendations and risk factors for complications, discuss pharmacologic and surgical treatment options, and examine clinical trial data on emerging agents. An animated case will allow learners to apply what they have learned in a simulated clinical encounter.

This CME program has been designed for endocrinologists who treat patients with type 2 diabetes. It aims to help learners evaluate the impact of weight loss and timely treatment intensification in patients with T2DM on glycemic and metabolic outcomes, and to increase knowledge of the mechanism of emerging GIP/GLP-1 receptor agonists and their impact on glycemic outcomes and body weight in order to advantageously integrate them into clinical practice when available.

This CME program has been designed to provide participants with the knowledge necessary to simultaneously address weight management and glycemic control in patients with type 2 diabetes and obesity/overweight. Participants will gain a greater understanding of guidelines-recommended pharmaceutical and lifestyle management strategies, and learn how incretin therapies with beneficial impacts on glycemic outcomes and body weight can be integrated into clinical practice. In addition to viewing a faculty presentation of relevant clinical data and guidelines, learners will participate in Med Games, an engaging gamified learning activity featuring interactive quizzes and video case studies that provide the opportunity to make decisions about patient care and get immediate feedback.

This enduring activity has been designed for HCPs treating metastatic castration-resistant prostate cancer (mCRPC) to improve: knowledge of the mechanisms of action of PARP inhibitor–based combinations for the treatment of patients with mCRPC with or without DNA damage response (DDR) alterations; awareness of new clinical data on the efficacy, safety, and tolerability of emerging PARP inhibitor–based combinations with different mechanisms of action for the treatment of patients with mCRPC; and their ability to develop individualized management plans for patients with mCRPC with or without DDR alterations that include PARP inhibitor–based combinations if appropriate.

This enduring MedGames is an interactive gamification-style CME activity that covers important topics in chronic spontaneous urticaria (CSU). The educational format of this program is engaging and covers the economic and physiological burden of CSU, diagnostic algorithms, guideline-recommended step-care management, and efficacy and safety of current and emerging biologic therapy.

In this educational activity, expert faculty will discuss the use of approved and authorized treatments for the management of patients hospitalized with COVID-19. A review of clinical trial data on the efficacy and safety of therapeutic options and strategies for selecting therapy based on disease severity and clinical factors will allow clinicians to reduce the need for invasive ventilation and improve patient outcomes.

This enduring activity will explore the diagnosis and management of NTM-LD. Whiteboard animations will identify common pitfalls that lead to delays in diagnosis and look at the mechanism of action of novel therapies for refractory disease. A case-based didactic lecture led by expert faculty will review guideline-recommended care, strategies to minimize adverse events, and clinical trial data on newer treatment options.

This case-based enduring activity will focus on the epidemiology, pathophysiology, diagnosis, and treatment of eosinophilic esophagitis (EoE). Patients with EoE are often diagnosed after symptom onset, leading to greater chronic inflammation, and treatment plans are frequently not tailored to individual needs. This activity is intended to help healthcare professionals diagnose EoE earlier and provide individualized treatment based on guidelines, recent clinical data and patient characteristics.

This educational activity will review clinical trial data on the use of authorized therapies for the management of patients hospitalized with COVID-19 and explore strategies to incorporate these therapeutic options into clinical practice. This program includes a whiteboard animation on the role of inflammation in the pathophysiology of severe COVID-19 and the mechanism of action of available treatment options.

This enduring activity will cover the treatment of patients with neuromyelitis optica spectrum disorder (NMOSD).

This enduring activity is designed to review the importance of chronic kidney disease (CKD) risk reduction in patients with T2D, how to evaluate opportunities to screen for CKD risk in patients with T2D and target reductions in albuminuria, the manageability of hyperkalemia and uniqueness of novel therapy, and key takeaways and practice changes.

This enduring activity will focus on the latest updates in the optimal management of cancer-associated venous thromboembolism (VTE) based on risk stratification, clinical trial data, and appropriate guideline-informed strategies to optimize clinical outcomes. This program will inform participants of the latest best practices as recommended by professional guidelines and will equip participants to integrate multidisciplinary care and shared decision-making in practice.

This case-based enduring activity is designed to provide clinicians with an overview of Short Bowel Syndrome and highlight its impact on patient quality of life.

This educational activity will explore best practices for the management of rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA). Expert faculty will review the latest information on clinical presentation, treatment recommendations, and clinical trial data on available therapies to help learners reduce both short- and long-term consequences of disease. An innovative simulation center will allow clinicians to apply what they have learned in an interactive, animated case.

Oncology nurses are in an inherently valuable position to be in the frontline for treatment of HER2-positive solid tumors. Given identified gaps and faculty feedback, the instructional design of this program is a multi-pronged educational approach designed for an oncology nursing audience. For additional resources, please visit www.oncologynurse-ce.com.

This online activity is designed to increase HCPs recognition of metabolic pathways involved in the pathophysiology of Gaucher disease; confidence discussing clinical trial data supporting improved outcomes in Gaucher disease; understanding of the potential for treatment to modify outcomes in Gaucher disease; and understanding of shared decision-making best practices for long-term management of Gaucher disease.

This enduring activity has been designed to help dermatologists, pediatric dermatologists, primary care physicians, advanced practice providers (NPs and PAs) and other healthcare providers who are involved in the care and treatment of patients with atopic dermatitis to assess patients for physical and psychosocial burdens of AD; identify candidates for systemic therapies; better evaluate recent clinical trial data on the efficacy and safety of JAK inhibitors for the management of moderate-to-severe AD; and apply evidence-based approaches to manage moderate-to-severe AD and monitor for adverse events.

This podcast will explore the management of patients with metastatic colorectal cancer (mCRC). Faculty will review strategies on personalizing the selection of treatment options based on molecular testing; and discuss the management of adverse events with targeted treatments for BRAF V600-mutant mCRC.

This enduring series will discuss the recognition and management of CKD risk in patients with T2D.

This activity discusses the growing impact of dengue fever worldwide and strategies to mitigate its spread. Featured topics of this program include signs and symptoms of dengue fever and differential diagnoses, the lifecycle of a dengue infection, and clinical trial data of approved and emerging vaccines.

This Community Whiteboard ECHO Series and Online Enduring activity is designed to increase the multi-disciplinary oncology care team recognition of the role of targeted and bispecific antibodies in management of relapsed/refractory DLBCL; strengthen their understanding of clinical trial outcomes and adverse events with targeted and bispecific antibodies; and improve their awareness of multidisciplinary best practices for managing adverse events from targeted therapies.

This activity features education regarding hormone therapy for children and adolescents with growth hormone (GH) deficiency. The program will discuss the diagnosis of GH deficiency, challenges of currently available therapies, clinical data of emerging therapies, and strategies to personalize care for childhood growth hormone deficiency (CGHD).

This case-based online activity is designed for retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with neovascular age-related macular degeneration and/or diabetic macular edema. The activity aims to improve treatment for patients who do not achieve optimal outcomes due to insufficient responses to therapy or insufficient adherence. In addition, it will elucidate the benefits and limitations of current therapeutic approaches, equip participants with strategies for improving the durability of treatment response in patients receiving intravitreal therapies, and provide education on new and emerging treatment strategies.

PODCAST ACTIVITY: These podcasts provide an up-to-date perspective on improving treatment for patients with neovascular age-related macular degeneration and/or diabetic macular edema who do not achieve optimal outcomes due to insufficient responses to therapy or insufficient adherence. This series of podcasts will elucidate the benefits and limitations of current therapeutic approaches for patients with nAMD or DME, equip participants with strategies for improving the durability of treatment response in patients receiving intravitreal therapies, and provide education on new and emerging treatment strategies.

This simulated activity depicts conversations between an oncologist, a pathologist, and a patient diagnosed with non-small cell lung cancer (NSCLC). You will watch as they engage with each other throughout the various stages of a patient’s journey, from the initial pathologic and oncologic workup at initial presentation to disease recurrence. You will participate in the simulation by answering questions throughout the activity. A brief slide presentations is available within each simulation center activity to enhance your understanding of immunological biomarkers.

This case-based virtual activity will cover the pathophysiology, clinical course, and underlying causes of NCFBE; summarize current evidence-based strategies for the diagnosis and treatment of patients with NCFBE; describe how neutrophilic inflammation and high levels of neutrophil serine proteases in patients with NCFBE provide the rationale for targeted treatment; and evaluate clinical data on therapies for NCFBE targeting neutrophilic inflammation neutrophil serine proteases.

This enduring activity has been designed to help obstetrician gynecologists and other HCPs involved in the care and treatment of patients with uterine fibroids (UF) and/or endometriosis to better support prompt initiation of treatment through early and accurate diagnosis. Key goals of this activity are to justify the need for new treatment options for patients with UFs and endometriosis based on the challenges associated with standard-of-care medical therapies and assess the results of clinical trials supporting the efficacy and safety profiles of newly approved and emerging combination therapies including GnRH antagonists for the long-term management of UFs and endometriosis. Finally, this program will outline individualized management plans for patients with UFs based on new clinical guidance & shared decision-making.

The majority of Veterans with migraine are seen in the primary care setting. Therefore, primary care professionals (PCPs) managing Veterans with migraine will need education on the most effective ways to treat it using currently available therapeutic options. This educational program seeks to effectively close those gaps.

This enduring activity will explore the management of moderate-to-severe atopic dermatitis (AD) in pediatric and adolescent patients. Innovative whiteboard animations will review the mechanism of action of systemic therapies for AD and the impact of COVID-19 on treatment selection. A review of clinical trial data, guideline recommendations, and patient-specific factors that impact management decisions will help clinicians develop personalized treatment plans and improve patient outcomes.

This initiative aims to increase the Department of Veteran’s Affairs multidisciplinary care team’s knowledge of both the efficacy and safety data from clinical trials for patients with small-cell lung cancer and review the NCCN clinical practice guidelines to optimize the outcomes of patients.

This activity provides a snapshot of the growing impact of dengue fever in Puerto Rico and strategies for prevention. Featured topics of this program include the burden of dengue fever and clinical trial data of approved and emerging vaccines.

This CME program provides a comprehensive and up-to-date perspective on the evolving management of patients with inflammatory bowel disease (IBD). We will be discussing unmet needs in the current identification and management of IBD; identifying tools to assist with differential diagnosis, clinical assessment, and selection of effective therapies for IBD; and exploring the underlying pathophysiology of IBD and the role of JAK inhibition in modifying therapeutic outcomes.

This enduring program aims to provide clinicians and patients with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for individuals with CRSwNP. Our goal is to provide information that empowers clinicians and patients to speak openly about treatment decisions and improve the standard of care for patients with this challenging disease.

This educational activity has been designed for nephrology fellows to ensure recognition of CKD risk in patients with T2D, understand novel strategies for modifying CKD risk, and review the risk of other chronic complications of T2D. We aim to evaluate current strategies for the management of CKD in T2D using novel therapeutic agents that modify long-term clinical outcomes, including third-generation mineralocorticoid antagonists; describe current disparities in CKD care in T2D and strategies for integrating novel strategies in practice, including third-generation mineralocorticoid antagonists; and lastly to summarize safety data with novel agents in the management of CKD in T2D, including best practices for managing hyperkalemia with novel mineralocorticoid antagonists.

The online activity will address the need for novel therapeutic options, including updates on advances in regenerative medicine, for patient with complex perianal fistula associated with Crohn’s disease. Learners will evaluate the current burden of perianal fistula in Crohn’s disease, pathophysiology, and the characteristics of current and emerging mechanisms of therapy.

This TeleECHO activity was designed to help oncologists and the multidisciplinary care team personalize gastric cancer treatment based on biomarker testing and use targeted therapies for HER2 positive disease treatment beyond the first line.

This online educational activity targets essential elements of the pearls of diagnosis and management of patients with α-thalassemias. Enhance your ability to evaluate the genetic and molecular pathophysiology of the various members of the α-thalassemia family and associated clinical presentations by genotype, as well as the risks for acute and chronic complications. After the timely, accurate diagnosis of α-thalassemia is made, assess the utility of traditional management strategies and the impact of emerging disease-modifying pharmacotherapy for the management of patients with α-thalassemias.

This CME program has been designed for primary care clinicians, pharmacists, and diabetes educators who care for patients with diabetes as well as patient audiences to increase knowledge of the relationship of glucose variability (GV) and time in range (TIR) to macro- and microvascular outcomes; enhance the ability to explain the importance of continuous glucose monitoring (CGM) and various CGM metrics; and select among basal insulin formulations based on their impacts on TIR and GV.

This TeleECHO series has been designed for US-based rheumatologists, nurses, and allied healthcare professionals involved in the management of patients with rheumatoid arthritis (RA), to better interpret data from clinical trials supporting the efficacy, safety, and tolerability of JAK inhibitors (JAKi) with different mechanisms of action in patients with moderate-to-severe RA. This series will help health professionals incorporate new evidence-based management recommendations on the use of JAKi for patients with moderate-to-severe RA into clinical practice, and it also supports patient-centered multidisciplinary team-based approaches to the management of those patients with moderate-to-severe RA.

RELEASED DATE: October 03, 2022
EXPIRATION DATE: October 03, 2023

This enduring activity will help health care professionals better evaluate the potential for multi-cancer early detection technologies to improve cancer detection and therapeutic outcomes in cancer care; analyze the accuracy for application of multicancer early detection technologies and ongoing trials; and choose appropriate patient populations that may be candidates for screening with multicancer early detection technologies and ensure clinicians are ready to discuss the meaning of test results with patients.

RELEASE DATE: October 05,  2022
EXPIRATION DATE: October 05, 2023

This program will discuss the pathogenesis of prostate cancer, the differences in mechanisms of action between the first- and second-generation anti-androgen drugs for prostate cancer, and identifying patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at elevated risk for metastasis, and management in order to reduce risk.

RELEASE DATE: October 06,  2022
EXPIRATION DATE: October 06, 2023

This educational activity will explore best practices to ensure prompt and accurate diagnosis of COVID-19 infection and the provision of outpatient care for patients with COVID-19 while incorporating shared decision-making principles and addressing disparities in care.

RELEASED DATE: October 06, 2022
EXPIRATION DATE: October 06, 2023

This program will discuss tumorigenesis in advanced non-small cell lung cancer (NSCLC) and the mechanism of actions of checkpoint inhibitors, the latest clinical data describing the efficacy and safety of first-line use of PD-1 inhibitor therapy, alone and in combination, and the use of immunotherapy in the first-line treatment of NSCLC with no actionable mutations.

RELEASE DATE: October 07,  2022
EXPIRATION DATE: October 07, 2023

This TeleECHO session will explore the management of patients with metastatic colorectal cancer (mCRC) through a short, didactic presentation and interactive case studies. Faculty will review strategies on personalizing the selection of treatment options based on molecular testing; and discuss the management of adverse events with targeted treatments for BRAF V600-mutant mCRC.

RELEASED DATE: October 10, 2022
EXPIRATION DATE: October 10, 2023

• Evaluate the panel of agents available for FH and determine their appropriateness based on type of FH, individual patient risk factors, comorbidities, and prior treatment
• Assess clinical trial evidence looking at long-standing and new therapies for the treatment of patients
  with FH
• Devise treatment plans that account for genetic aberrations impacting the activity of LDL-Rs in patients with FH

RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023

• Evaluate the panel of agents available for FH and determine their appropriateness based on type of FH, individual patient risk factors, comorbidities, and prior treatment
• Assess clinical trial evidence looking at long-standing and new therapies for the treatment of patients
  with FH
• Devise treatment plans that account for genetic aberrations impacting the activity of LDL-Rs in patients with FH

RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023

• Evaluate the panel of agents available for FH and determine their appropriateness based on type of FH, individual patient risk factors, comorbidities, and prior treatment
• Assess clinical trial evidence looking at long-standing and new therapies for the treatment of patients
  with FH
• Devise treatment plans that account for genetic aberrations impacting the activity of LDL-Rs in patients with FH

RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023

• Evaluate the panel of agents available for FH and determine their appropriateness based on type of FH, individual patient risk factors, comorbidities, and prior treatment
• Assess clinical trial evidence looking at long-standing and new therapies for the treatment of patients
  with FH
• Devise treatment plans that account for genetic aberrations impacting the activity of LDL-Rs in patients with FH

RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023

This online educational program focuses on the latest data on mealtime insulin in patients with type 2 diabetes mellitus. In this program, clinicians will address appropriate treatment intensification strategies in consideration of patient-related factors, the latest clinical data, and key parameters for monitoring clinical response to mealtime insulin. Through this program, clinicians will improve their level of comfort with initiating mealtime insulins to optimize glycemic outcomes, including in underserved populations. Innovative learning strategies will reinforce the latest best practices to support clinician and patient understanding of the latest strategies in glycemic management.

RELEASED DATE: October 14, 2022
EXPIRATION DATE: October 14, 2023

This enduring activity has been designed for healthcare professionals involved in the management of patients with psoriasis to improve knowledge of the function of TYK2 in psoriasis; awareness of clinical profiles of emerging TYK2 inhibitors; their ability to discern the potential place of TYK2 inhibitors in current treatment algorithms; and the adoption of shared decision-making with patients.

RELEASED DATE:  October 25, 2022
EXPIRATION DATE:  October 25, 2023

This activity features education regarding the links between obesity and diabetes, the role of the incretin system in these metabolic disorders, and use of incretin therapies to manage diabetes-related obesity.

RELEASED DATE: October 26, 2022
EXPIRATION DATE: October 26, 2023

This enduring activity is designed to help HCPs improve their ability to evaluate the risk of pneumococcal infection from a population perspective and consider the importance of various serotypes in managing population health; assess clinical data and specific data with pneumococcal serotypes to determine treatment options in the context of guidelines; and to apply best practices in implementing pneumococcal vaccination schedules to improve health outcomes.

RELEASED DATE: October 26, 2022
EXPIRATION DATE: October 26, 2023

This activity will address the challenges faced by clinicians in managing older patients with T2DM. Participants will be equipped with an enhanced ability to apply current guideline recommendations and clinical data to management plans, personalize diabetes treatment for older adults in long-term care facilities and in the community, and gain greater knowledge of the rationale for using fixed ratio combinations of basal insulin and GLP-1 receptor agonists in older adults with T2DM.

RELEASE DATE: October 26,  2022
EXPIRATION DATE: October 26, 2023

This enduring activity is faculty-led didactic and case-based interactive activities focusing on the management of patients with Type 2 diabetes and obesity. This CME program has been designed to help clinicians recognize overweight/obesity as an important treatment target; utilize guidelines and clinical data on the use of incretin therapies for treatment intensification; and implement shared decision making to better engage patients and personalize care.

RELEASED DATE:  October 27, 2022
EXPIRATION DATE:  October 27, 2023

This activity discusses the care of patients hospitalized with SARS-CoV-2 infection. The program will address the burden of COVID-19 in the US as well as the currently circulating strains. The program is designed to help clinicians integrate the latest treatment guidelines and management strategies for this patient population into their practice. The program will present the results of the latest clinical trials of novel therapies for COVID 19 to inform clinicians’ choice of therapy for patients hospitalized with SARS-CoV-2 to reduce the risk of mortality.

RELEASED DATE: November 1, 2022
EXPIRATION DATE: November 1, 2023

This educational activity will explore the appropriate place in the therapy paradigm for immunotherapy in patients with head and neck cancer, as well as managing adverse effects of immunotherapies.

RELEASED DATE: November 04, 2022
EXPIRATION DATE: November 04, 2023

• Summarize the relevance of molecular markers and genetic data relevant to selection of therapy in CLL or AML
• Review relevant treatment best practices in both newly diagnosed and relapsed/refractory AML in consideration of disease- and patient-specific factors to inform shared decision-making
• Evaluate potential adverse events associated CLL and AML therapies to implement appropriate monitoring and counseling

RELEASED DATE: November 4, 2022
EXPIRATION DATE: November 4, 2023

This enduring activity has been designed to address the latest therapy, guidelines, and clinical trials in the management of PIK3CA-related overgrowth spectrum (PROS). Med Learning Group aims to enhance healthcare professionals’ ability to evaluate best practices in the diagnosis of PROS, including phenotypic variability, disease impacts, and challenges in genetic testing; to summarize the multi-systemic burden of PROS on quality of life and evaluate same when considering an evidence-based treatment plan; and finally, to analyze the safety and efficacy of approved therapy for the management of PROS as well as opportunities for clinical trial enrollment.

RELEASED DATE: November 22, 2022
EXPIRATION DATE: November 22, 2023

This enduring activity will be a faculty-led didactic and case-based lecture focusing on the management of patients with Multiple Myeloma.

RELEASED DATE:  November 22, 2022
EXPIRATION DATE:  November 22, 2023

This educational activity is designed to evaluate novel targets in NHL management, including consideration of the role of bispecific antibodies and combinations in development; assess clinical outcomes of key trials in NHL management, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma; and lastly to explain the current understanding of potential adverse events associated with novel therapies, including considerations regarding multidisciplinary management of adverse events.

RELEASED DATE: December 13, 2022
EXPIRATION DATE: December 13, 2023

This enduring activity has been designed to improve: knowledge of the new and emerging HER2-directed therapies in patients with advanced HER2-altered non-small cell lung cancer beyond the first-line; awareness of three mechanisms of HER2 activation that drive disease progression in NSCLC; and their ability to apply clinical practice guidelines to the patient care setting in the management of individuals with metastatic, HER2-positive NSCLC.

RELEASED DATE: December 14, 2022
EXPIRATION DATE: December 14, 2023

In this podcast episode, we will review how to monitor a patient’s response to therapy for moderate-to-severe atopic dermatitis and how to coordinate care across specialties in this pediatric patient population.

RELEASED DATE: December 19, 2022
EXPIRATION DATE: December 19, 2023

This enduring activity provides an opportunity for community oncologists and advanced practice providers to interact with experts to quickly get up to speed on the latest advances in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). During this program, faculty will describe the prognostic and predictive roles of common EGFR-mutations and the high-risk clinical and disease characteristics to be aware of in patients with NSCLC. Through a review of clinical trial data and recent guidelines updates, faculty will increase confidence in individualizing treatment that addresses the underlying molecular pathology of the disease. Participants will be encouraged to share their own cases and engage with faculty throughout this activity. Innovative learning platforms and practice tools will reinforce incorporation of targeted treatments into practice to help improve outcomes for patients with EGFR-mutated NSCLC.

RELEASED DATE:  December 15, 2022
EXPIRATION DATE:  January 10, 2024

This enduring will focus on the management of moderate to severe atopic dermatitis.

RELEASED DATE: December 23, 2022
EXPIRATION DATE: December 23, 2023

This enduring activity addresses the mechanisms of resistance and characteristics of refractory disease in patients with multiple myeloma; reviews the mechanisms of action of both current and emerging therapies in the treatment of patients with relapsing/refractory multiple myeloma; and lastly evaluates the clinical data for developing agents in the management of patients with late relapse/refractory multiple myeloma.

RELEASED DATE: January 05 , 2023
EXPIRATION DATE: January 05 , 2024

This enduring activity addresses the mechanisms of resistance and characteristics of refractory disease in patients with multiple myeloma; reviews the mechanisms of action of both current and emerging therapies in the treatment of patients with relapsing/refractory multiple myeloma; and lastly evaluates the clinical data for developing agents in the management of patients with late relapse/refractory multiple myeloma.

RELEASED DATE: January 17, 2023
EXPIRATION DATE: January 17, 2024

This enduring activity has been designed for community-based hematology-oncologists, nurse practitioners, and physician assistants to ensure confidence in the management of relapsed/refractory multiple myeloma. It discusses the mechanisms of resistance and characteristics of refractory disease in patients with multiple myeloma; review the mechanisms of action of both current and emerging therapies in the treatment of patients with relapsing/refractory multiple myeloma; and lastly evaluates the clinical data for developing agents in the management of patients with late relapse/refractory multiple myeloma.

RELEASED DATE: January 18, 2023
EXPIRATION DATE: January 27, 2024

The educational program is designed to help Veterans Affairs clinicians in treating and managing patients with relapsed/refractory multiple myeloma.

RELEASED DATE: January 31, 2023
EXPIRATION DATE: January 31, 2024

This online enduring educational snapshot focuses on multiple topics across the spectrum of venous thromboembolism (VTE) management, including but not limited to, diagnosis, evidence-based guidelines, extended management/secondary prevention, and VTE in cancer. This program is designed specifically to address micro-learning needs of those who care for cancer patients who are at increased risk for developing VTE and cancer-associated thrombosis (CAT).

RELEASED DATE: January 31, 2023
EXPIRATION DATE: January 31, 2024

This educational activity will assist the target HCP’s ability to: assess the clinical advantages and disadvantages associated with luteinizing hormone-releasing hormone (LHRH) agonists and gonadotropin-releasing hormone (GnRH) antagonists used as androgen deprivation therapy (ADT) for patients with advanced prostate cancer (PC); evaluate the differential level of risk for cardiovascular adverse events when selecting ADT for patients with advanced PC; support equitable PC care through improved access to ADT and, finally, improve adherence to ADT through consideration of patient preferences regarding the route of administration.

RELEASED DATE: February 14, 2023
EXPIRATION DATE: February 14, 2024

The DETECT TeleECHO Series connects specialists with on-the-ground community HCPs to educate them on best practices for managing patients with early cognitive impairment and Alzheimer’s disease. The program uses a case-based, interactive format designed to enhance clinician knowledge and improve their confidence in treating this population.

RELEASED DATE: February 15, 2023
EXPIRATION DATE: February 15, 2024

• Evaluate the panel of agents available for FH and determine their appropriateness based on type of familial hypercholesterolemia (FH), individual patient risk factors, comorbidities, and prior treatment
• Assess clinical trial evidence looking at long-standing and new therapies for the treatment of patients with FH
• Devise treatment plans that account for genetic aberrations impacting the activity of LDL-Rs in patients with FH

RELEASED DATE: February 22, 2023
EXPIRATION DATE: February 22, 2024

This educational activity will explore the relationship between the underlying pathophysiology of primary immunodeficiency disorder (PIDD) and its clinical manifestations; incorporate evidence-based guidance on diagnostic and management best practices for pediatric and adult patients with PIDs into clinical practice; and integrate strategies for recognizing and overcoming health inequities for pediatric and adult patients with PIDs in underserved/minority communities into clinical practice.

RELEASED DATE: February 28, 2023
EXPIRATION DATE: February 28, 2024

This educational activity will serve to increase the ability of healthcare professionals to relate the pathophysiology of Fabry Disease (FD) to the development of cardiac and renal manifestations, and to develop strategies to identify, monitor, and address risk factors impacting long-term cardiac/renal progression and clinical outcomes, in order to more effectively implement evidence-based long-term FD management plans.

RELEASED DATE: March 10, 2023
EXPIRATION DATE: March 10, 2024

This enduring activity will enhance clinicians’ knowledge of the relationship between chronic rhinosinusitis with nasal polyps (CRSwNP) endotypes and pathophysiology; familiarity with data from clinical trials assessing the efficacy, safety, and tolerability of available and emerging therapeutic options; and knowledge and implementation of strategies to identify those who are appropriate candidates for biologic therapy.

RELEASED DATE: March 10, 2023
EXPIRATION DATE: March 10, 2024

• Interpret data from landmark intensification trials for the treatment of patients with mHSPC
• Facilitate access to treatment intensification for patients with mHSPC in clinical practice
• Design individualized management plans for patients with mHSPC using evidence-based guidance, recommended sequencing strategies, and clinical decision-making tools that can enhance patient involvement

RELEASED DATE: March 16, 2023
EXPIRATION DATE: March 16, 2024

This podcast focuses on identifying. the most appropriate patients for currently available second-line therapies in gastric/GEJ cancers.

RELEASED DATE: March 17, 2023
EXPIRATION DATE: March 17, 2024

This activity explores the potential of novel therapies for the second-line management of advanced gastric cancers, including a review of current clinical practice guidelines and specifics on choosing the most appropriate therapy for the most appropriate patient.

RELEASED DATE: March 17, 2023
EXPIRATION DATE: March 17, 2024

The DETECT Immersive Simulation experience provides up-to-date information on the diagnosis and management of mild cognitive impairment and Alzheimer’s disease (AD) targeted to specific specialties. The program uses a case-based, interactive format designed to enhance clinician knowledge and improve their confidence in treating this population.

RELEASED DATE: March 20, 2023
EXPIRATION DATE: March 20, 2024

This podcast will discuss the burden of illness and the burden of treatment associated with primary immune deficiency disorder (PIDD). Additionally, the podcast will address the intersectionality of having PIDD and belonging to an underserved/minority community.

RELEASED DATE: March 20, 2023
EXPIRATION DATE: March 20, 2024

This program will focus on the application and implementation of multicancer early detection (MCED) testing in primary care. The content will review the basics of MCED technology and how it improves cancer detection; describe which patients may be candidates for this type of screening; discuss what tests are available; and review how these tests can be used in primary care.

RELEASED DATE: March 23, 2023
EXPIRATION DATE: March 23, 2024

These online enduring podcasts focus on the role of GLP-1 receptor agonists in the care of patients with type 2 diabetes, including but not limited to, the glycemic and extra-glycemic effects and strategies to avoid adverse events of GLP-1 receptor agonists while enhancing the patient/provider partnership using a shared decision-making approach to the selection of GLP-1 receptor agonists.

RELEASED DATE: February 27, 2023
EXPIRATION DATE: March 23, 2024

The educational activity is designed to meet the educational needs of healthcare professionals to address disparities of education within the Veterans Affairs Health-care system specifically chronic idiopathic constipation (CIC). We aim to help HCPs within the VA system increase their ability to: evaluate current best practices in the diagnosis of CIC in consideration of pathophysiology and therapeutic mechanisms; recognize current real-world and clinical trial evidence regarding the efficacy and safety of available CIC therapies; and summarize current strategies for effective implementation of shared decision making in meeting patient-centered therapeutic goals.

RELEASED DATE: March 27, 2023
EXPIRATION DATE: March 27, 2024

This TeleECHO series is designed to update clinicians who care for patients at risk for and with COVID-19 with the most up-to-date guidelines on the prevention, diagnosis, and management of patients in the outpatient setting.

RELEASED DATE: March 30, 2023
EXPIRATION DATE: March 30, 2024

This TeleECHO session explores the utility of potassium-restricted diets in patients with hyperkalemia based on the most recent studies. It also reviews the role of potassium binders in managing hyperkalemia.

RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024

This program uses a unique, interactive approach to providing the most up-to-date information on the use of systemic therapies and multidisciplinary care in atopic dermatitis (AD).

RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024

This innovative and engaging symposium is an animated simulation challenge, which will assist Healthcare providers to utilize assessment tools to evaluate disease burden and severity; compare and contrast systemic treatment options for the management of moderate-to-severe atopic dermatitis (AD); and develop proactive treatment plans that manage signs and symptoms, minimize disease flares, and improve quality of life in pediatric and adult patients with AD.

RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024

This enduring activity has been designed to meet the educational needs of healthcare providers in the Department of Veterans Affairs, including psychiatrists involved in the management of patients with schizophrenia. We aim to help HCPs within the VA system assess the clinical benefits and disadvantages associated with dopamine-modulating antipsychotic medications approved for the management of schizophrenia and also interpret data from clinical trials assessing the clinical profiles of new and emerging therapies for the management of schizophrenia that have unique targets and mechanisms of action.

RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024

The enduring DETECT Clinical Conversations Exchange connects specialists with community health care providers to provide education on best practices for managing patients with early cognitive impairment and Alzheimer’s disease. The program uses a case-based, interactive format designed to enhance clinician knowledge and improve their confidence in treating this population.

RELEASED DATE: April 03, 2023
EXPIRATION DATE: April 03, 2024

Med Learning Group hosted this 3D Satellite Summit Meeting that contained innovative and engaging animations in partnership with EHA. This enduring program has 2 highly regarded faculty speakers and contains 2.0 hours of content. The educational activity allows for a high level of interactivity as there will be breaks in the faculty presentations where the learners utilize animations with interactive question/answer sessions that the faculty will review with the audience. In addition, we are partnering with the Public Health Foundation (PHF) for program awareness; they will broadcast the meeting through their network healthcare providers.

RELEASED DATE: April 7, 2023
EXPIRATION DATE: April 7, 2024

This activity has been designed for healthcare professionals who care for patients with small cell lung cancer (SCLC). The program serves to improve HCP’s knowledge of relevant efficacy and safety data concerning second-line treatment options for patients with extensive-stage SCLC; comprehension of clinical trial evidence behind current guideline recommendations; and their ability to apply second-line efficacy and safety data to small-cell lung cancer care.

RELEASED DATE: April 07, 2023
EXPIRATION DATE: April 07, 2024

This enduring activity will focus on the application and implementation of multicancer early detection (MCED) testing in primary care. The content will review the basics of MCED technology and how it improves cancer detection; describe which patients may be candidates for this type of screening; discuss what tests are available; and review how these tests can be used in primary care.

RELEASED DATE: April 10, 2023
EXPIRATION DATE: April 10, 2024

This enduring HoloVision™ activity is an online program designed to advance healthcare practitioners’ ability to: evaluate mechanisms of action in multiple myeloma; examine the rationale for earlier-line use of CAR T-cell therapy in multiple myeloma; summarize the latest efficacy and safety data with CAR T-cell therapy; consider the design of current clinical trials in early-relapsed high-risk multiple myeloma; and formulate strategies for sequencing of CAR T-cell therapy, including adverse event management.

RELEASED DATE: April 14, 2023
EXPIRATION DATE: April 14, 2024

This Enduring of the DETECT Grand Rounds connects specialists with on-the-ground community HCPs to educate them on best practices for managing patients with early cognitive impairment and Alzheimer’s disease. The program uses an animated, case-based, interactive format designed to enhance clinician knowledge and improve their confidence in treating this population.

RELEASED DATE: April 19, 2023
EXPIRATION DATE: April 19, 2024

The educational activity focuses on the role of GLP-1 receptor agonists in the care of patients with type 2 diabetes, including but not limited to, the glycemic and extra-glycemic effects and strategies to avoid adverse events of GLP-1 receptor agonists while enhancing the patient/provider partnership using a shared decision-making approach to the selection of GLP-1 receptor agonists.

RELEASED DATE: April 21, 2023
EXPIRATION DATE: April 21, 2024

These podcasts are designed to help healthcare professionals assess the relationship between checkpoint inhibition and immunopathology in advanced melanoma, update them on the latest clinical data with anti-LAG3 antibody combinations in advanced melanoma, and provide strategies to optimize the safety of combination immunotherapy approaches in advanced melanoma. Additionally, healthcare professionals will be able to understand the importance of patient advocacy as we converse with a patient about their cancer diagnosis and treatment.

RELEASED DATE: April 21, 2023
EXPIRATION DATE: April 21, 2024

This enduring activity has been designed for healthcare professionals who manage patients with obesity. The program will seek to help HCPs increase their recognition of obesity as a disease; recognize the burden of comorbidities associated with obesity; and increase their ability to apply clinical data to guide treatment selection for obesity. Learners will also recognize the need for implementing guideline-based management of obesity across providers and increase their comfort with the integration of weight reduction pharmacotherapy.

RELEASED DATE: April 10, 2023
EXPIRATION DATE: April 28, 2024

Through case-based education, this enduring TeleECHO activity will discuss unmet needs in Inflammatory Bowel Disease (IBD) management with considerations for modification of clinical outcomes with novel therapies; evaluate current guidelines for differential diagnosis, clinical assessment, and choice of therapeutic options in IBD; and provide clinicians with better understanding of the importance of JAK/STAT signaling in inflammatory conditions.

RELEASED DATE: May 01, 2023
EXPIRATION DATE: May 01, 2024

This podcast episode will focus on the overview of the disease state and talk about initial management strategies for patients with relapsed/refractory multiple myeloma.

RELEASED DATE: May 01, 2023
EXPIRATION DATE: May 01, 2024

This podcast focuses on current guidelines for diagnosing COVID-19 and why people with certain underlying conditions face a higher risk of hospitalization and death if they get infected.

RELEASED DATE: May 05, 2023
EXPIRATION DATE: May 05, 2024

This enduring activity will provide HCPs with knowledge and context around the science and technology behind MCED testing and the potential for improved clinical outcomes with earlier detection; tools to determine the accuracy of MCED tests and how to communicate results to patients; and tips on best practices for overcoming patient and physician barriers to MCED testing for better integration in primary care.

RELEASED DATE: May 10, 2023
EXPIRATION DATE: May 10, 2024

This program uses an immersive, specialty-based approach to explore the current understanding of COVID risk assessment, diagnosis, and outpatient treatment.

RELEASED DATE: May 12, 2023
EXPIRATION DATE: May 12, 2024

The goal of this enduring activity series is to help HCPs ensure optimal patient outcomes in outpatient management of COVID-19 infection by increasing understanding of the need for early diagnosis and intervention for patients at high risk for progression to severe COVID-19.

RELEASED DATE: May 18, 2023
EXPIRATION DATE: May 18, 2024

This COVID-19 Snapshot series provides a comprehensive and up-to-date perspective on the ever-changing outpatient management of patients with COVID-19.

RELEASED DATE: May 19, 2023
EXPIRATION DATE: May 19, 2024

This online program will provide clinicians who care for people with chronic lymphocytic leukemia and mantle cell leukemia with important updates about current and future management of the diseases. It includes two animations and case study discussions.

RELEASED DATE: May 30, 2023
EXPIRATION DATE: May 30, 2024

This podcast episode will focus on the overview of the disease state and talk about initial management strategies for patients with relapsed/refractory multiple myeloma.

RELEASED DATE: May 01, 2023
EXPIRATION DATE: May 31, 2024

This Enduring of the DETECT Summit connects specialists with community healthcare providers to provide education on best practices for managing patients with early cognitive impairment and Alzheimer’s disease (AD). The program uses a case-based format designed to enhance clinician knowledge and improve their confidence in treating this population.

RELEASED DATE: June 01, 2023
EXPIRATION DATE: June 01, 2024

This enduring activity is designed aims to help HCPs reduce time to diagnosis in patients with suspected NTM-LD, individualize treatment selection for patients with NTM-LD in frontline and refractory settings based on clinical guidelines and patient characteristics, evaluate the role of amikacin liposome inhalation suspension (ALIS) in the treatment of patients with NTM-LD, and optimize strategies to avoid and manage the adverse effects of antibiotic therapy inpatients with NTM-LD and facilitate the completion of therapy.

RELEASED DATE: June 09, 2023
EXPIRATION DATE: June 09, 2024

This podcast will discuss the risks of severe disease in patients with obesity who develop COVID-19.

RELEASED DATE: June 09, 2023
EXPIRATION DATE: June 09, 2024

This enduring activity takes learners on a compelling journey in managing chronic graft-versus-host disease (cGVHD) by explaining the evidence-based diagnostic criteria for cGVHD for prompt diagnosis; discussing the clinical safety and efficacy data of recently approved and investigational therapeutic agents, and finally, developing strategies to create treatment plans that address the psychosocial impact of disease and prioritize improvement in quality of life. Learners are invited to explore challenging aspects of this condition with the goal of informing selection of the most appropriate treatment regimens targeting disease etiopathogenesis. This immersive experience highlights the importance of early recognition in the effective management of cGVHD.

RELEASED DATE: June 16, 2023
EXPIRATION DATE: June 16, 2024

This educational program will help healthcare providers to better examine clinical trials data supporting the use of new systemic immunotherapies for the treatment of patients with advanced nonmelanoma skin cancers (NMSCs), failing or not amenable to surgery or radiation; describe risk-assessment of patients with NMSCs who may derive greater benefit from new systemic therapies as opposed to Mohs surgery; and review the coordination and collaboration of multidisciplinary team members in the management of patients with advanced NMSCs failing or not amenable to surgery or radiation.

RELEASED DATE: June 30, 2023
EXPIRATION DATE: June 30, 2024

This enduring program will provide clinicians who care for patients with chronic lymphocytic leukemia and mantle cell leukemia with important updates about current and future management of the diseases. It includes two animations and case study discussions.

RELEASED DATE: July 07, 2023
EXPIRATION DATE: July 07, 2024

This enduring will focus on strategies to identify CKD risk in patients with T2D and familiarity with novel strategies for modifying CKD risk and the risk of other chronic complications of T2D.

RELEASED DATE: July 12, 2023
EXPIRATION DATE: July 12, 2024

This enduring activity will address methodology to specifically support healthcare professionals charged with the care of pediatric patients with influenza so that they can better expedite an accurate influenza diagnosis, evaluate and appropriately incorporate antiviral agents for the pediatric population inclusive of postexposure prophylaxis, and recognize the full range of therapeutic tools at their disposal to care for pediatric patients.

RELEASED DATE: July 12, 2023
EXPIRATION DATE: July 12, 2024

This enduring activity has been designed to help gastroenterologists and advanced practitioners who treat patients with ulcerative colitis distinguish histologic healing as a treatment target; assess data on the association between histologic remission in ulcerative colitis and patient outcomes; and utilize appropriate tools for assessing histologic activity in patients with ulcerative colitis to guide treatment and monitoring plans.

RELEASED DATE: March 23, 2023
EXPIRATION DATE: July 21, 2024

This activity is designed to meet the educational needs of medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team.

• Analyze the mechanistic features of bispecific antibodies and rationale for use in relapsed/refractory large B-cell lymphomas
• Evaluate current clinical trial data informing use of bispecific antibodies in in relapsed/refractory large B-cell lymphomas
• Summarize best practices for management of potential adverse events with bispecific antibodies in large B-cell lymphomas in a multidisciplinary practice setting

RELEASED DATE: June 27, 2023
EXPIRATION DATE: June 27, 2024

This educational activity is designed for psychiatrists, nurse practitioners, physician assistants, nurses, and other healthcare professionals and focuses on the management of patients with major depressive disorder (MDD), with the goal of reaching full remission in patients showing an adequate response to first-line therapies utilizing patient-centered, shared decision-making management strategies.

RELEASED DATE: July 27, 2023
EXPIRATION DATE: July 27, 2024

This enduring activity is designed for academic and community medical oncologists, pathologists, nurse practitioners, physician assistants, and pharmacists who care for patients with non-small cell lung cancer (NSCLC). We aim to increase the target healthcare provider’s ability to: describe the role of TROP2 in the clinicopathophysiology of NSCLC and its role in treatment as a targetable protein; assess the clinical trials data for TROP2-targeted therapy, in the second-line, for those patients with relapsed/refractory NSCLC; and identify strategies for managing adverse events, patient and treatment selection that include TROP2-directed antibody-drug conjugates.

RELEASED DATE: August 01, 2023
EXPIRATION DATE: August 01, 2024

In this enduring program, we will discuss how healthcare providers within the Department of Veterans Affairs can improve their treatment of patients with acute myeloid leukemia (AML) by providing updates on key biological features and biomarkers of AML to inform patient assessment with novel therapies. In addition, we will review the latest data on AML management and challenges in effectively communicating the rationale for therapeutic decisions with patients and caregivers.

RELEASED DATE: August 02, 2023
EXPIRATION DATE: August 02, 2024